Jurgen Klaus Beck
Directeur/Membre du Conseil chez Paion Holdings UK Ltd.
Profil
Jurgen Klaus Beck has held director positions at Paion Holdings UK Ltd.
and Paion UK Ltd.
since 2018.
Postes actifs de Jurgen Klaus Beck
| Sociétés | Poste | Début |
|---|---|---|
Paion Holdings UK Ltd.
 Paion Holdings UK Ltd. Financial ConglomeratesFinance Part of PAION AG, Paion Holdings UK Ltd. functions as an investment holding company. The company is based in Edinburgh, UK. The British company was founded in 1996. Abdelghani Omari has been the CEO of the company since 2012. | Directeur/Membre du Conseil | 25/01/2018 |
Paion UK Ltd.
 Paion UK Ltd. Pharmaceuticals: MajorHealth Technology Part of PAION AG, Paion UK Ltd. is a specialty pharmaceutical company that develops and commercializes innovative drugs for out-patient and hospital-based sedation and critical care services. Paion was founded in 1995 and is based in Cambridge, UK, with another site in Germany. Paion's vision is to become an acknowledged "PAIONeer" in sedation and critical care services. The British company's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate. The company is mainly focusing on completing the development program for procedural sedation and planning to continue the clinical development program for remimazolam in the indication general in the EU. | Directeur/Membre du Conseil | 25/01/2018 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Paion Holdings UK Ltd.
Paion Holdings UK Ltd. Financial ConglomeratesFinance Part of PAION AG, Paion Holdings UK Ltd. functions as an investment holding company. The company is based in Edinburgh, UK. The British company was founded in 1996. Abdelghani Omari has been the CEO of the company since 2012. | Finance |
Paion UK Ltd.
Paion UK Ltd. Pharmaceuticals: MajorHealth Technology Part of PAION AG, Paion UK Ltd. is a specialty pharmaceutical company that develops and commercializes innovative drugs for out-patient and hospital-based sedation and critical care services. Paion was founded in 1995 and is based in Cambridge, UK, with another site in Germany. Paion's vision is to become an acknowledged "PAIONeer" in sedation and critical care services. The British company's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate. The company is mainly focusing on completing the development program for procedural sedation and planning to continue the clinical development program for remimazolam in the indication general in the EU. | Health Technology |